Sperax Usd Stock Forecast

Sell candidate since Jun 16, 2026 Loss -4.15%

The Sperax USD stock price gained 0.669% on the last trading day (Monday, 22nd Jun 2026), rising from $0.0025 to $0.0025. During the last trading day the stock fluctuated 1.70% from a day low at $0.0025 to a day high of $0.0025. The price has been going up and down for this period, and there has been a -7.67% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 1 million more shares were traded than the day before. In total, 3 million shares were bought and sold for approximately $6.64 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -17.07% during the next 3 months and, with a 90% probability hold a price between $0.0019 and $0.0024 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

SPAUSD Signals & Forecast

There are mixed signals in the stock today. The Sperax USD stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.0026 and $0.0027. A break-up above any of these levels will issue buy signals. A buy signal was issued from a pivot bottom point on Sunday, June 21, 2026, and so far it has risen 0.669%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Sperax USD has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Sperax USD stock

Sperax USD finds support from accumulated volume at $0.0025 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.00004239 between high and low, or 1.70%. For the last week, the stock has had daily average volatility of 2.63%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (SPAUSD) For The Upcoming Trading Day Of Tuesday 23rd

For the upcoming trading day on Tuesday, 23rd we expect Sperax USD to open at $0.0025, and during the day (based on 14 day Average True Range), to move between $0.0024 and $0.0026, which gives a possible trading interval of +/-$0.0001 (+/-5.47%) up or down from last closing price. If Sperax USD takes out the full calculated possible swing range there will be an estimated 5.47% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $0.0025 (0.66%) than the resistance at $0.0027 (7.21%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Sperax USD stock A Buy?

Sperax USD holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.428 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 23, 2026 - $0.0025 ( 0.565%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk